How much revenue did Immutep generate this year?
Immutep has achieved a revenue of 4.04 M AUD this year.
Immutep Revenue 2024
Immutep Revenue
4.04 M AUD
Ticker
IMM.AX
ISIN
AU000000IMM6
WKN
A2H81H
In 2024, Immutep's sales reached 4.04 M AUD, a 2,008.28% difference from the 191,720 AUD sales recorded in the previous year.
The Immutep Revenue history
| YEAR | REVENUE (undefined AUD) | GROSS MARGIN (%) |
|---|---|---|
| 2030e | 468.29 | -6,99 |
| 2029e | 143.7 | -22,79 |
| 2028e | 49.72 | -65,88 |
| 2027e | 5.08 | -644,30 |
| 2026e | 5.3 | -617,57 |
| 2025e | 4.53 | -723,44 |
| 2024e | 4.04 | -810,24 |
| 2023 | 0.19 | -17082,20 |
| 2022 | 0.25 | -10468,18 |
| 2021 | 0.31 | -4273,75 |
| 2020 | 13.94 | -234,96 |
| 2019 | 6.03 | -542,71 |
| 2018 | 7.03 | -465,81 |
| 2017 | 4.22 | -775,86 |
| 2016 | 2.03 | -1614,16 |
| 2015 | 1.55 | -2106,62 |
| 2014 | 2.73 | -1199,63 |
| 2013 | 4.01 | -816,71 |
| 2012 | 4.2 | -779,76 |
| 2011 | 1.07 | -3060,75 |
| 2010 | 0.52 | -6298,08 |
| 2009 | 0.03 | -109166,67 |
| 2008 | 0.06 | -54583,33 |
| 2007 | 0.16 | -20468,75 |
| 2006 | 3.88 | -844,07 |
| 2005 | 1.07 | -3060,75 |
| 2004 | 0.35 | -9357,14 |
Immutep Revenue, EBIT, Net Income AU000000IMM6 · A2H81H
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Immutep, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immutep from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immutep’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Immutep. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Immutep’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Immutep’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immutep’s growth potential.
Immutep Revenue, EBIT and net profit per share
| Date | Immutep Revenue | Immutep EBIT | Immutep Net Income |
|---|---|---|---|
| 2030e | 468.29 M undefined | 0 undefined | 0 undefined |
| 2029e | 143.7 M undefined | 366.94 M undefined | 389.49 M undefined |
| 2028e | 49.72 M undefined | 97.98 M undefined | 305.8 M undefined |
| 2027e | 5.08 M undefined | -59.82 M undefined | -44.14 M undefined |
| 2026e | 5.3 M undefined | -66.29 M undefined | -56.41 M undefined |
| 2025e | 4.53 M undefined | -60.45 M undefined | -53.9 M undefined |
| 2024e | 4.04 M undefined | -48.45 M undefined | -46.59 M undefined |
| 2023 | 191,720 undefined | -48.2 M undefined | -39.9 M undefined |
| 2022 | 254,390 undefined | -38.62 M undefined | -32.21 M undefined |
| 2021 | 312,840 undefined | -24.38 M undefined | -29.9 M undefined |
| 2020 | 13.94 M undefined | -14.87 M undefined | -13.47 M undefined |
| 2019 | 6.03 M undefined | -18.57 M undefined | -18.34 M undefined |
| 2018 | 7.03 M undefined | -11.52 M undefined | -12.75 M undefined |
| 2017 | 4.22 M undefined | -9.35 M undefined | -9.37 M undefined |
| 2016 | 2.03 M undefined | -62.02 M undefined | -62.02 M undefined |
| 2015 | 1.55 M undefined | -14.11 M undefined | -32.15 M undefined |
| 2014 | 2.73 M undefined | -13.74 M undefined | -13.34 M undefined |
| 2013 | 4.01 M undefined | -15.11 M undefined | -15.23 M undefined |
| 2012 | 4.2 M undefined | -18.45 M undefined | -19.94 M undefined |
| 2011 | 1.07 M undefined | -14.12 M undefined | -21.08 M undefined |
| 2010 | 520,000 undefined | -8.44 M undefined | -12.16 M undefined |
| 2009 | 30,000 undefined | -2.35 M undefined | -2.95 M undefined |
| 2008 | 60,000 undefined | -1.88 M undefined | -1.89 M undefined |
| 2007 | 160,000 undefined | -2.87 M undefined | -3.14 M undefined |
| 2006 | 3.88 M undefined | -2.26 M undefined | -4.25 M undefined |
| 2005 | 1.07 M undefined | -7.08 M undefined | -6.23 M undefined |
| 2004 | 350,000 undefined | -5.67 M undefined | -4.97 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 350,000 AUD | -5.67 M AUD | -4.97 M AUD |
| 2005 | 1.07 M AUD | -7.08 M AUD | -6.23 M AUD |
| 2006 | 3.88 M AUD | -2.26 M AUD | -4.25 M AUD |
| 2007 | 160,000 AUD | -2.87 M AUD | -3.14 M AUD |
| 2008 | 60,000 AUD | -1.88 M AUD | -1.89 M AUD |
| 2009 | 30,000 AUD | -2.35 M AUD | -2.95 M AUD |
| 2010 | 520,000 AUD | -8.44 M AUD | -12.16 M AUD |
| 2011 | 1.07 M AUD | -14.12 M AUD | -21.08 M AUD |
| 2012 | 4.2 M AUD | -18.45 M AUD | -19.94 M AUD |
| 2013 | 4.01 M AUD | -15.11 M AUD | -15.23 M AUD |
| 2014 | 2.73 M AUD | -13.74 M AUD | -13.34 M AUD |
| 2015 | 1.55 M AUD | -14.11 M AUD | -32.15 M AUD |
| 2016 | 2.03 M AUD | -62.02 M AUD | -62.02 M AUD |
| 2017 | 4.22 M AUD | -9.35 M AUD | -9.37 M AUD |
| 2018 | 7.03 M AUD | -11.52 M AUD | -12.75 M AUD |
| 2019 | 6.03 M AUD | -18.57 M AUD | -18.34 M AUD |
| 2020 | 13.94 M AUD | -14.87 M AUD | -13.47 M AUD |
| 2021 | 312,840 AUD | -24.38 M AUD | -29.9 M AUD |
| 2022 | 254,390 AUD | -38.62 M AUD | -32.21 M AUD |
| 2023 | 191,720 AUD | -48.2 M AUD | -39.9 M AUD |
| 2024e | 4.04 M AUD | -48.45 M AUD | -46.59 M AUD |
| 2025e | 4.53 M AUD | -60.45 M AUD | -53.9 M AUD |
| 2026e | 5.3 M AUD | -66.29 M AUD | -56.41 M AUD |
| 2027e | 5.08 M AUD | -59.82 M AUD | -44.14 M AUD |
| 2028e | 49.72 M AUD | 97.98 M AUD | 305.8 M AUD |
| 2029e | 143.7 M AUD | 366.94 M AUD | 389.49 M AUD |
| 2030e | 468.29 M AUD | 0 AUD | 0 AUD |
Immutep stock margins AU000000IMM6 · A2H81H
The Immutep margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immutep. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immutep.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Immutep's sales revenue. A higher gross margin percentage indicates that the Immutep retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Immutep's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Immutep's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immutep's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immutep. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immutep's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Immutep Margin History
| Immutep Gross margin | Immutep Profit margin | Immutep EBIT margin | Immutep Profit margin |
|---|---|---|---|
| 2030e | -17,082.2 % | 0 % | 0 % |
| 2029e | -17,082.2 % | 255.35 % | 271.05 % |
| 2028e | -17,082.2 % | 197.08 % | 615.11 % |
| 2027e | -17,082.2 % | -1,176.92 % | -868.42 % |
| 2026e | -17,082.2 % | -1,250.13 % | -1,063.82 % |
| 2025e | -17,082.2 % | -1,335.34 % | -1,190.66 % |
| 2024e | -17,082.2 % | -1,198.65 % | -1,152.68 % |
| 2023 | -17,082.2 % | -25,139.98 % | -20,809.7 % |
| 2022 | -10,468.18 % | -15,182.22 % | -12,661.99 % |
| 2021 | -4,273.75 % | -7,792.48 % | -9,558.44 % |
| 2020 | -17,082.2 % | -106.7 % | -96.62 % |
| 2019 | -17,082.2 % | -307.65 % | -303.99 % |
| 2018 | -17,082.2 % | -163.8 % | -181.29 % |
| 2017 | -17,082.2 % | -221.58 % | -221.91 % |
| 2016 | -17,082.2 % | -3,056.63 % | -3,056.56 % |
| 2015 | -17,082.2 % | -907.92 % | -2,068.14 % |
| 2014 | -17,082.2 % | -503.3 % | -488.64 % |
| 2013 | -17,082.2 % | -376.81 % | -379.8 % |
| 2012 | -17,082.2 % | -439.29 % | -474.76 % |
| 2011 | -17,082.2 % | -1,319.63 % | -1,970.09 % |
| 2010 | -17,082.2 % | -1,623.08 % | -2,338.46 % |
| 2009 | -17,082.2 % | -7,833.33 % | -9,833.33 % |
| 2008 | -17,082.2 % | -3,133.33 % | -3,150 % |
| 2007 | -17,082.2 % | -1,793.75 % | -1,962.5 % |
| 2006 | -17,082.2 % | -58.25 % | -109.54 % |
| 2005 | -17,082.2 % | -661.68 % | -582.24 % |
| 2004 | -17,082.2 % | -1,620 % | -1,420 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | -17,082.2 % | -1,620 % | -1,420 % |
| 2005 | -17,082.2 % | -661.68 % | -582.24 % |
| 2006 | -17,082.2 % | -58.25 % | -109.54 % |
| 2007 | -17,082.2 % | -1,793.75 % | -1,962.5 % |
| 2008 | -17,082.2 % | -3,133.33 % | -3,150 % |
| 2009 | -17,082.2 % | -7,833.33 % | -9,833.33 % |
| 2010 | -17,082.2 % | -1,623.08 % | -2,338.46 % |
| 2011 | -17,082.2 % | -1,319.63 % | -1,970.09 % |
| 2012 | -17,082.2 % | -439.29 % | -474.76 % |
| 2013 | -17,082.2 % | -376.81 % | -379.8 % |
| 2014 | -17,082.2 % | -503.3 % | -488.64 % |
| 2015 | -17,082.2 % | -907.92 % | -2,068.14 % |
| 2016 | -17,082.2 % | -3,056.63 % | -3,056.56 % |
| 2017 | -17,082.2 % | -221.58 % | -221.91 % |
| 2018 | -17,082.2 % | -163.8 % | -181.29 % |
| 2019 | -17,082.2 % | -307.65 % | -303.99 % |
| 2020 | -17,082.2 % | -106.7 % | -96.62 % |
| 2021 | -4,273.75 % | -7,792.48 % | -9,558.44 % |
| 2022 | -10,468.18 % | -15,182.22 % | -12,661.99 % |
| 2023 | -17,082.2 % | -25,139.98 % | -20,809.7 % |
| 2024e | -17,082.2 % | -1,198.65 % | -1,152.68 % |
| 2025e | -17,082.2 % | -1,335.34 % | -1,190.66 % |
| 2026e | -17,082.2 % | -1,250.13 % | -1,063.82 % |
| 2027e | -17,082.2 % | -1,176.92 % | -868.42 % |
| 2028e | -17,082.2 % | 197.08 % | 615.11 % |
| 2029e | -17,082.2 % | 255.35 % | 271.05 % |
| 2030e | -17,082.2 % | 0 % | 0 % |
Immutep Aktienanalyse
What does Immutep do?
Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2001 and is headquartered in Sydney, Australia. The history of Immutep began with the discovery of a new type of T-cell receptor, known as lymphocyte activation gene-3 (LAG-3) receptors, which are involved in the activation of T-cells. The company used this knowledge to develop a platform of immunotherapeutics based on the stimulation of LAG-3 receptors, with the goal of enhancing the body's immune response against cancer and autoimmune diseases. Immutep's business model is based on the development and commercialization of immunotherapeutics that target LAG-3 receptors. The company focuses on the clinical development of therapeutics targeting various stages of cancer, such as lung cancer, prostate cancer, and breast cancer. Additionally, the company is also developing therapeutics for the treatment of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. Immutep is divided into various divisions to coordinate its activities in the areas of research and clinical development. These divisions include clinical development, research and development, and the production of immunotherapeutics. In the clinical development division, Immutep focuses on demonstrating the safety and efficacy of its immunotherapeutics in the treatment of cancer and autoimmune diseases. The company conducts clinical trials to evaluate the effectiveness of its therapeutics and obtain regulatory approval. Immutep's research and development department focuses on developing innovative immunotherapeutics based on LAG-3 receptors. The company has developed several patented technologies that enhance the effectiveness of the therapeutics and increase the body's tolerance to them. Immutep also operates a production division specializing in the manufacturing of immunotherapeutics. The company has production facilities in Europe and Asia, allowing it to distribute its therapeutics worldwide. The company offers a range of immunotherapeutics based on the stimulation of LAG-3 receptors. These therapeutics have been specifically developed for the treatment of cancer and autoimmune diseases and have the potential to enhance the body's immune response against these conditions. Immutep's products include IMP321, an immunotherapeutic specifically developed for the treatment of prostate cancer, and IMP701, an immunotherapeutic specifically developed for the treatment of lung cancer. Additionally, the company has several new therapeutics in clinical development, including IMP761 for the treatment of systemic lupus erythematosus and IMP731 for the treatment of Crohn's disease. Immutep is a leading company in the development of immunotherapeutics based on LAG-3 receptors. The company has a strong pipeline of therapeutics in clinical development and is well-positioned to benefit from the growing demand for immunotherapeutics for the treatment of cancer and autoimmune diseases. With its patented technologies and expertise in clinical development of immunotherapeutics, Immutep is well-equipped to grow and solidify its position as a leading company in this field. Immutep ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Immutep's Sales Figures
The sales figures of Immutep originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Immutep’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Immutep's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Immutep’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Immutep stock
How much was the turnover of the company Immutep compared to the previous year?
The revenue of Immutep has increased by 2,008.28% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Immutep?
The revenue of Immutep is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Immutep measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Immutep so important for investors?
The revenue of Immutep is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Immutep pay?
Over the past 12 months, Immutep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immutep is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immutep?
The current dividend yield of Immutep is .
When does Immutep pay dividends?
Immutep pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immutep?
Immutep paid dividends every year for the past 0 years.
What is the dividend of Immutep?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immutep located?
Immutep is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immutep kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immutep from 8/25/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/25/2024.
When did Immutep pay the last dividend?
The last dividend was paid out on 8/25/2024.
What was the dividend of Immutep in the year 2023?
In the year 2023, Immutep distributed 0 AUD as dividends.
In which currency does Immutep pay out the dividend?
The dividends of Immutep are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immutep
Our stock analysis for Immutep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
